Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4SCAR-276 in CD276 Positive Solid Tumors
NCT04432649Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 4SCAR-276 in solid tumor, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Number of patients with adverse events at 3 years. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
4SCAR-276
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04432649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432649.